This article is for educational purposes only. Fasting is not appropriate for everyone. Consult your GP before starting any fasting protocol, particularly if you have diabetes, are pregnant, or have a history of disordered eating.
Intermittent fasting for weight loss remains one of the most searched and debated dietary strategies in Australia — and with good reason. Unlike most diet trends that fade within a news cycle, intermittent fasting has accumulated a genuine and growing body of clinical evidence over the past decade. But that evidence has also become more nuanced, particularly following the landmark 2025 Cochrane systematic review that clarified what fasting actually does — and does not — achieve compared to conventional caloric restriction.
If you have been reading conflicting claims about intermittent fasting results in 2026, this guide cuts through the noise. We cover what the best available research actually shows, how each major protocol works, who benefits most, who should not fast, and how fasting fits into the modern weight management landscape alongside Ozempic and other interventions.
The Cochrane Collaboration — the gold standard for systematic evidence synthesis in medicine — published its comprehensive review of intermittent fasting for weight loss in 2025. This review synthesised data from over 100 randomised controlled trials involving more than 9,000 participants and is the most rigorous evaluation of fasting protocols conducted to date.
The headline findings:
Intermittent fasting produces comparable weight loss to continuous caloric restriction. When calorie intake is held equivalent between groups, there is no statistically significant difference in total weight lost at six or twelve months between participants following an intermittent fasting protocol versus those following a standard daily caloric restriction approach. This is an important finding: it means fasting is not a metabolic magic trick. The weight loss it produces is primarily explained by the caloric deficit it creates.
No significant metabolic advantage over matched caloric restriction. The Cochrane review found no consistent evidence that intermittent fasting produces superior improvements in insulin sensitivity, lipid profiles, blood pressure, or inflammatory markers compared to a standard daily restricted-calorie diet when total energy intake was equivalent. Some individual trials do show metabolic benefits with fasting beyond those expected from weight loss alone, but these effects are inconsistent across studies and cannot yet be considered established.
Adherence is the key variable. The most consistent finding across the entire body of evidence is that adherence determines outcomes. Intermittent fasting does not produce better weight loss than continuous restriction — but for many individuals, it is significantly easier to adhere to. A structured fasting window removes the need for constant calorie counting, reduces decision fatigue around food choices, and many people find it more psychologically manageable than all-day portion control. This adherence advantage is clinically meaningful even if the underlying mechanism is simply caloric restriction.
Safety profile is broadly acceptable. The Cochrane review found no serious adverse events attributable to fasting in the populations studied, though it confirmed that specific populations (discussed later) require medical supervision or should avoid fasting entirely.
What this means practically: Intermittent fasting is a legitimate, evidence-supported weight loss strategy — not because it operates through some unique metabolic pathway, but because it is an effective and sustainable way for many people to achieve a caloric deficit over time. The best diet for weight loss is the one a person can actually maintain.
Not all fasting approaches are equivalent. The research covers several distinct protocols, each with different mechanisms, adherence profiles, and practical implications.
The most widely practised protocol. You eat within an 8-hour window each day and fast for the remaining 16 hours. A common schedule is eating from 12 pm to 8 pm, skipping breakfast, and consuming nothing caloric outside that window. Black coffee, plain tea, and water are typically permitted during the fasting hours.
The 16:8 approach is considered the most accessible entry point because it requires no calorie counting and aligns naturally with many people's schedules. Most of the fasting hours are spent asleep, which reduces hunger significantly.
Typical results: 0.5–1 kg weight loss per week in the early phase when paired with attention to food quality, flattening to a slower rate as adaptation occurs.
Best suited to: People who naturally skip breakfast, those who find all-day portion control difficult, shift workers who can align their eating window with their waking hours.
Popularised by British physician Dr Michael Mosley, the 5:2 diet involves eating normally for five days per week and significantly restricting calories — typically to 500–600 kcal — on two non-consecutive fast days. On fast days, most people consume one or two small meals rather than abstaining entirely.
Typical results: Meta-analyses of 5:2 trials show weight loss outcomes broadly comparable to daily restriction, with some trials suggesting better adherence in populations who find daily restriction psychologically fatiguing.
Best suited to: People with flexible weekly schedules, those who prefer clear "on/off" days rather than daily time windows, and people who find the binary simplicity of fast versus non-fast days easier to maintain.
A more aggressive version of time-restricted eating where all daily calories are consumed in approximately one hour. This creates a 23:1 fasting-to-eating ratio. OMAD produces significant caloric restriction for most people due to the physical limitation of consuming enough food in a single sitting.
Important caveat: OMAD significantly increases the risk of protein and micronutrient inadequacy and makes it substantially harder to meet daily protein intake targets — a critical issue for muscle preservation discussed in detail in Section 6. OMAD is not recommended for most people without careful nutritional planning.
Participants alternate between a "fast day" (0–25% of normal caloric intake) and a "feast day" (normal or slightly elevated intake). True ADF is the most studied protocol in research settings but has poorer real-world adherence than 16:8 or 5:2, making it less practical for most people despite producing robust trial results.
Understanding the mechanism behind intermittent fasting weight loss helps set realistic expectations and guides smarter protocol choices.
The dominant driver of weight loss with intermittent fasting is straightforward: most people consume fewer total calories when their eating is confined to a shorter window. When you cannot eat between 8 pm and 12 pm the following day, you lose the opportunity for evening snacking, late-night eating, and the spontaneous caloric additions that accumulate during unrestricted access to food. Population studies consistently show that restricting eating to daytime hours reduces daily energy intake by 300–500 kcal without deliberate portion control in many individuals.
This caloric deficit — sustained over weeks and months — drives fat mass reduction through exactly the same mechanism as any other dietary approach. For a detailed breakdown of how to calculate TDEE, set a safe deficit size, and manage metabolic adaptation over time, the caloric deficit guide for sustainable weight loss covers the full science.
While the Cochrane review cautions against overclaiming unique metabolic benefits, the physiology of fasting does produce several notable effects:
Insulin reduction and metabolic switching. During a fast, circulating insulin levels fall. Low insulin states favour fatty acid mobilisation from adipose tissue. After 10–12 hours of fasting, glycogen stores become substantially depleted and the liver begins producing ketones from fatty acid oxidation. This metabolic switch — sometimes called "metabolic flexibility" — may improve insulin resistance over time, though the extent to which this represents a benefit beyond that produced by weight loss itself remains debated.
Autophagy induction. Autophagy — the cellular self-cleaning process that breaks down and recycles damaged cellular components — is substantially upregulated during fasting. Animal studies and human observational data suggest meaningful autophagy induction begins at approximately 16–18 hours of fasting, which is why the 16:8 protocol sits at a physiologically interesting threshold. Researchers studying fasting-mimicking compounds and related fasting-mimicking peptide research have highlighted autophagy as one of the most therapeutically interesting downstream effects of extended fasting states, given its potential implications for cellular repair, metabolic health, and longevity. NAD+ bioavailability is closely linked to autophagic flux — the NAD+ metabolism and weight loss article covers how declining NAD+ levels affect cellular energy sensing, SIRT1 activation, and the mitochondrial pathways that autophagy depends on for fuel during extended fasting states.
Growth hormone pulsing. Fasting significantly elevates growth hormone (GH) secretion, particularly during overnight fasting periods. GH is strongly anabolic and lipolytic — it promotes fat oxidation while protecting lean muscle mass. Studies show GH levels can increase 2–5 fold during a 24-hour fast. This is one mechanism through which strategic fasting may help preserve muscle during weight loss, though adequate protein intake during the eating window remains essential (see Section 6).
Circadian alignment. Eating aligned with daylight hours — morning and midday eating windows — appears to produce better metabolic outcomes than evening-shifted windows, even at identical caloric intakes. This circadian effect on insulin sensitivity, gut motility, and bile acid recycling represents a genuine additional lever that time-restricted eating can exploit if the eating window is aligned with the first half of the day.
The 16:8 protocol has the largest volume of clinical trial data of any fasting approach, making it the most evidence-grounded protocol for most people seeking intermittent fasting weight loss results.
A 2020 trial published in Cell Metabolism randomised obese participants to 16:8 time-restricted eating versus an unrestricted eating schedule for twelve weeks. The fasting group lost significantly more weight and showed greater improvements in insulin resistance — but crucially, the fasting group also consumed approximately 350 fewer calories per day on average, confirming that caloric restriction was the primary driver.
A 2022 trial in NEJM Evidence (the TREAT trial) compared 16:8 fasting to continuous caloric restriction over twelve months in 139 participants with obesity. Both groups lost a comparable amount of weight (approximately 8 kg on average), and the metabolic outcomes — blood pressure, lipids, HbA1c, insulin resistance — were broadly similar between groups. The 16:8 group achieved their results without being asked to count calories, which the authors noted as a meaningful practical advantage.
More recent 2024–2025 meta-analyses incorporating 40+ 16:8 trials report:
For Australian adults following 16:8 without additional calorie counting, realistic expectations are:
Total weight loss of 5–10% of initial body weight over six months is a realistic and clinically meaningful target for most people following 16:8 consistently.
The single most important modifier of 16:8 outcomes beyond adherence is protein intake during the eating window. Trials that have deliberately matched protein between groups show smaller differences between fasting and non-fasting conditions, but also confirm that high-protein 16:8 produces better body composition outcomes (more fat loss, less muscle loss) than low-protein 16:8. A target of 1.6–2.2 g of protein per kg of body weight daily, distributed across meals within the eating window, is the evidence-based recommendation for preserving lean mass. See our full protein intake guide for detailed strategies.
Dr Michael Mosley popularised the 5:2 diet following his BBC Horizon documentary Eat, Fast and Live Longer in 2012. The protocol as Mosley described it involves:
The logic behind non-consecutive fast days is to avoid the cumulative fatigue and hunger that comes with back-to-back restriction, while still achieving a meaningful weekly caloric deficit. If a person eats normally five days and restricts to 500 kcal on two days, they achieve roughly 2,500–3,000 kcal of weekly deficit — equivalent to losing approximately 0.35–0.4 kg per week from fat alone, assuming no compensatory overeating on non-fast days (which trials suggest is modest but real).
Multiple randomised controlled trials have directly compared 5:2 to daily caloric restriction:
Based on the aggregate evidence and clinical observation, 5:2 tends to work particularly well for:
5:2 tends to be less suitable for people with irregular schedules, shift workers, athletes with high daily training demands, or anyone for whom two severely restricted days per week creates significant hunger-driven overeating on adjacent days.
One of the most important — and frequently underemphasised — considerations with intermittent fasting is the risk of skeletal muscle loss. This is not a hypothetical concern.
During any caloric deficit, the body draws energy from both fat stores and lean tissue (muscle protein). The ratio of fat to muscle lost depends primarily on three factors: the size of the caloric deficit, the adequacy of protein intake, and the presence or absence of resistance training stimulus.
During prolonged fasting, the body's amino acid requirements for gluconeogenesis (producing glucose from non-carbohydrate sources) increase. If dietary protein is insufficient, skeletal muscle is catabolised to supply these amino acids. Several trials of aggressive fasting protocols — particularly OMAD and alternate day fasting — have documented meaningful lean mass reductions alongside fat loss, which is clinically undesirable given that muscle tissue is metabolically active and its preservation is central to long-term weight maintenance.
The evidence-based approach to preventing muscle loss during intermittent fasting involves three components:
1. Hit your daily protein target within your eating window. As noted above, 1.6–2.2 g/kg/day is the recommended range. For an 80 kg person, this means 128–176 g of protein daily, consumed entirely within an 8-hour (16:8) or spread across non-fast days (5:2). This is achievable but requires deliberate planning — see our protein weight loss guide for practical meal strategies.
2. Distribute protein across at least two to three meals within the eating window. The muscle protein synthesis response to a protein-rich meal peaks and saturates at approximately 40 g of high-quality protein per sitting. Consuming all your daily protein in a single meal (as in OMAD) substantially limits the cumulative anabolic stimulus compared to spreading it across multiple meals. Even within a 16:8 window, eating at 12 pm, 3 pm, and 7:30 pm allows three protein-adequate meals.
3. Maintain resistance training. Fasting without resistance exercise results in greater lean mass loss than fasting with resistance training. This applies even to moderate protocols like 16:8. The mechanical stimulus of resistance training is the most powerful signal for muscle protein synthesis, and it partially compensates for the catabolic pressure of a caloric deficit.
Intermittent fasting is contraindicated or requires careful medical supervision in several populations. This list is not exhaustive — always consult your GP before starting any fasting protocol.
Type 1 Diabetes. Extended fasting produces unpredictable glycaemic fluctuations and significantly increases the risk of hypoglycaemia. Fasting protocols should not be undertaken by people with T1DM outside of a supervised clinical setting.
Type 2 Diabetes on Insulin or Sulfonylureas. These medications work in part by lowering blood glucose independent of food intake. Fasting while taking insulin or sulfonylureas creates a serious hypoglycaemia risk. Some T2DM patients managed on metformin alone or through diet may be able to incorporate structured fasting with GP guidance, but insulin or sulfonylurea users should not fast without medical supervision and likely medication adjustment.
History of Disordered Eating. Structured fasting — particularly protocols with defined "allowed" and "not allowed" food periods — can trigger or exacerbate restrictive eating patterns, obsessive food thinking, and eating disorder relapse. The binary rules of fasting are poorly suited to anyone with anorexia, bulimia, or orthorexia history.
Pregnancy and Breastfeeding. Caloric restriction and prolonged fasting are contraindicated during pregnancy. Foetal development requires consistent nutrient supply, and ketosis during pregnancy carries specific risks. Breastfeeding increases caloric demands and is not compatible with significant fasting-induced deficits.
Children and Adolescents (Under 18). Growing bodies require consistent nutrient availability. Fasting protocols have not been studied in paediatric populations outside clinical settings and should not be imposed on children or teenagers.
Significantly Underweight Individuals (BMI below 18.5). Any further caloric restriction in underweight individuals is clinically inappropriate.
People on Multiple Medications. Some medications require food for absorption or to minimise gastrointestinal side effects. Always review your medication list with your GP or pharmacist before starting a fasting protocol.
Jumping directly into a strict 16:8 protocol can produce excessive hunger, poor adherence, and early abandonment. A graduated approach is more successful:
This progressive approach reduces the severity of the hunger adaptation period and gives the gut microbiome time to adjust to the changed feeding pattern.
This is one of the most common questions about intermittent fasting in Australia. The core principle is that the fasting window should be free of calories and significant insulin-stimulating substances. In practice:
For weight loss purposes: calories break the fast. For autophagy or cellular benefits, the threshold may be lower — even small protein amounts may blunt autophagy signalling. Most people fasting primarily for weight management do not need to worry about trace amounts; the focus should be on maintaining caloric discipline within the eating window.
With Ozempic and Wegovy (semaglutide) now available in Australia, and tirzepatide entering the market, a reasonable question arises: does intermittent fasting still have a place, or has pharmaceutical intervention made it obsolete for people who can access these medications? For those interested in how semaglutide sits alongside other metabolic peptide compounds in the research landscape, the peptide weight loss stack overview covers the mechanistic distinctions between GLP-1 agonists and GH-axis peptides like AOD-9604 and Tesamorelin.
The answer is nuanced — and the evidence increasingly suggests that fasting and GLP-1 therapy are complementary rather than competing approaches.
Insulin sensitivity potentiates GLP-1 effects. GLP-1 receptor agonists work in part through pathways that depend on baseline insulin sensitivity. Improving insulin resistance through time-restricted eating creates a more favourable hormonal environment for GLP-1 signalling. Several researchers have proposed that patients with better baseline insulin sensitivity respond more robustly to GLP-1 agonist therapy — meaning fasting prior to or alongside these medications may improve outcomes.
Fasting addresses the behavioural dimension. GLP-1 medications powerfully reduce appetite and food noise, but they do not teach or reinforce the behavioural structures around eating that support long-term weight maintenance. Many patients who discontinue GLP-1 therapy (due to cost, side effects, or availability) regain weight rapidly because the environmental and habitual cues that drove overeating are unchanged. Intermittent fasting builds behavioural scaffolding — defined eating windows, reduced reliance on constant food decisions — that may support weight maintenance after medication discontinuation.
For the majority who cannot access GLP-1 medications: Cost remains a significant barrier in Australia. Wegovy remains expensive and not universally PBS-subsidised. For the large proportion of Australians who cannot or choose not to access pharmaceutical weight management, intermittent fasting — particularly 16:8 — represents the best-evidenced non-pharmaceutical dietary strategy currently available.
Natural GLP-1 enhancement. Time-restricted eating, particularly early eating windows aligned with daylight hours, appears to improve endogenous GLP-1 secretion. This means fasting may produce some of its metabolic benefits through mild enhancement of the body's own incretin signalling. For a deeper look at supporting natural GLP-1 production, our detailed guide covers the dietary and lifestyle levers available.
Intermittent fasting is not a substitute for GLP-1 medications in patients with obesity-related comorbidities who are eligible for and can access pharmacotherapy. It does not produce weight loss of 15–20% of body weight as seen with semaglutide. However, for appropriate patients, it is a safe, low-cost, well-evidenced strategy that produces clinically meaningful weight loss (5–10% of body weight) and metabolic improvements with no out-of-pocket pharmaceutical cost and no injection requirements.
The emerging consensus is that structured time-restricted eating can be usefully combined with GLP-1 therapy to support medication efficacy, address behavioural patterns, and provide a sustainable framework for the post-medication phase of treatment.
Yes — the evidence is clear that intermittent fasting produces meaningful weight loss for most people who adhere to it. The 2025 Cochrane systematic review, the most comprehensive evaluation of the evidence to date, confirmed that intermittent fasting produces weight loss outcomes comparable to daily caloric restriction. The mechanism is primarily caloric restriction achieved by narrowing the eating window, though there are additional metabolic effects (autophagy, insulin reduction, growth hormone pulsing) that may provide independent benefits. For people who find all-day portion control difficult, intermittent fasting is often significantly easier to maintain — which makes it highly effective in practice even if the underlying physiology is straightforward.
During the fasting window, you can drink black coffee, plain tea (black, green, or herbal), water, and sparkling water without breaking your fast for weight loss purposes. Plain electrolytes (without sugar) are also acceptable and are particularly helpful if you experience headaches or fatigue during the early weeks. Avoid anything containing calories: milk, juice, soft drinks, protein shakes, and energy drinks all break the fast. Artificial sweeteners are debated; they contain no calories, but some research suggests they may trigger small insulin responses in certain individuals — if you find your hunger spikes after diet drinks, try eliminating them from the fasting window.
Short-term fasting does not meaningfully reduce resting metabolic rate. The metabolic slowdown associated with prolonged caloric restriction ("adaptive thermogenesis") occurs with sustained caloric deficits regardless of the dietary pattern used — it is not specific to intermittent fasting. Some research suggests that the growth hormone pulsing and catecholamine release that occurs during fasting may actually modestly increase metabolic rate in the short term. Over the long term, the primary driver of metabolic adaptation is lean mass loss — which is why maintaining adequate protein intake and resistance training during any fasting protocol is so important. Fasting that preserves muscle mass will produce less metabolic adaptation than fasting that causes significant lean tissue loss.
Yes, and for most people exercise and intermittent fasting are compatible. The main considerations are timing and intensity. Low-to-moderate intensity exercise (walking, cycling, yoga) is well-tolerated in the fasting state and may enhance fat oxidation during the session. High-intensity training, heavy resistance training, or endurance sessions longer than 60–90 minutes are better suited to periods closer to or within the eating window, where glycogen stores are available and post-exercise protein intake can be immediate. For a detailed look at how to structure interval training alongside a fasting protocol without accumulating excess cortisol load, the HIIT weight loss guide covers timing, session length, and recovery considerations. If you train fasted in the morning (as many people do on a 16:8 protocol where the eating window starts at noon), breaking the fast with a protein-rich meal immediately after training is recommended to stimulate muscle protein synthesis and support recovery.
Neither protocol is universally superior — the best protocol is the one you can consistently adhere to. In direct head-to-head comparisons, 16:8 and 5:2 produce comparable weight loss over six and twelve months. 16:8 tends to suit people who prefer daily structure and find it easier to avoid eating outside a defined daily window. 5:2 tends to suit people who prefer flexibility most of the week and can manage two significantly restricted days. Some people find 5:2's fast days psychologically difficult and compensate with increased eating on adjacent days, which diminishes the caloric deficit; these people typically do better with 16:8. If you start with one protocol and find adherence difficult after four to six weeks, switching to the other is a reasonable approach — the evidence supports both.
This article was reviewed against published clinical literature including the Cochrane Database of Systematic Reviews. References include: Harris L et al., Cochrane Database Syst Rev 2025; Lowe DA et al., JAMA Intern Med 2020; Wilkinson MJ et al., Cell Metab 2020; Harvie MN et al., Int J Obes 2011. All weight loss figures are population averages and individual results vary.
Eli Lilly's orforglipron is the first non-peptide oral GLP-1 agonist with full Phase 3 data. This guide covers the ATTAIN-1 obesity trial, the ACHIEVE-1 T2D trial, weight loss versus injectable semaglutide and tirzepatide, side-effect profile, and Australian timeline implications.
A detailed breakdown of the TRIUMPH-1 Phase 3 trial results for retatrutide — the triple-hormone agonist that achieved up to 28.3% mean weight loss at 80 weeks and ~30.3% in a higher-BMI subgroup at 104 weeks.
Is body recomposition possible? The evidence says yes — under specific conditions. Here's the science behind losing fat and gaining muscle at the same time, including protein targets, training requirements, and realistic timelines.